{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:11:27Z","timestamp":1768003887109,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":813,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jtct.2020.12.017","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T14:05:46Z","timestamp":1609423546000},"page":"273.e1-273.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed\/Refractory Immunoglobulin D Multiple Myeloma"],"prefix":"10.1016","volume":"27","author":[{"given":"Wei","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Bhansali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hujun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangjun","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2020.12.017_bib0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.jtct.2020.12.017_bib0002","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.12.017_bib0003","first-page":"e4011","article-title":"Presentation Patterns, Diagnostic Markers, Management Strategies, and Outcomes of IgD Multiple Myeloma: A Systematic Review of Literature","volume":"11","author":"Selene","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jtct.2020.12.017_bib0004","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/archinte.1975.00330010089012","article-title":"IgD multiple myeloma. Review of 133 cases","volume":"135","author":"Jancelewicz","year":"1975","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtct.2020.12.017_bib0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdq393","article-title":"Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients","volume":"22","author":"Kim","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2020.12.017_bib0006","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ejh.12255","article-title":"Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents","volume":"92","author":"Zagouri","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2020.12.017_bib0007","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00277-018-3582-4","article-title":"Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era","volume":"98","author":"Chen","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2020.12.017_bib0008","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3346\/jkms.2008.23.5.819","article-title":"Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience","volume":"23","author":"Chong","year":"2008","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jtct.2020.12.017_bib0009","article-title":"Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience","volume":"39","author":"Zhao","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.jtct.2020.12.017_bib0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000446599","article-title":"Immunoglobulin D multiple myeloma: disease profile, therapeutic response, and survival","volume":"136","author":"Wang","year":"2016","journal-title":"Acta Haematol-basel"},{"key":"10.1016\/j.jtct.2020.12.017_bib0011","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jtct.2020.12.017_bib0012","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2020.12.017_bib0013","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.12.017_bib0014","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2020.12.017_bib0015","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2020.12.017_bib0016","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ajh.25108","article-title":"Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"93","author":"Cao","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2020.12.017_bib0017","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.12.017_bib0018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2020.12.017_bib0019","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer discovery"},{"key":"10.1016\/j.jtct.2020.12.017_bib0020","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131546","article-title":"Combined infusion of anti-CD19 and anti-Bcma CART cells after early or later transplantation in the front line was superior to salvage therapy for high risk MM","volume":"134","author":"Shi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.12.017_bib0021","article-title":"A Bcma and CD19 bispecific CAR-T for relapsed and refractory multiple myeloma","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2020.12.017_bib0022","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood advances"},{"key":"10.1016\/j.jtct.2020.12.017_bib0023","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1038\/s41409-020-0930-5","article-title":"Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma with renal impairment","volume":"55","author":"Li","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.jtct.2020.12.017_bib0024","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636720300634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636720300634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:59:48Z","timestamp":1763002788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636720300634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2666636720300634"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2020.12.017","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed\/Refractory Immunoglobulin D Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2020.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}